Recently, Eyebright Medical received honors in two prestigious evaluations.

The "2025 Top 100 Civilian-run Enterprises in Beijing" list, organized by the Beijing Federation of Industry and Commerce, has recognized Eyebright Medical among the "Top 100 Specialized, Refined, Distinctive, and Innovative Enterprises," ranking 7th due to its achievements in core technology, revenue, and social responsibility. This list highlights the innovative vitality and core competitiveness of Beijing's civilian-run economy.

Additionally, Eyebright Medical gained authoritative recognition at the "2025 China Capital Market Development Forum" held in Shanghai, where it was awarded the title of "2025 A-Share Value Demonstration Case" for its exceptional long-term investment value. The "China Listed Companies Excellence Award" is noted for its rigorous evaluation and is one of the most influential awards in the domestic asset management industry.

These honors affirm Eyebright Medical's commitment to innovation, core business focus, and continuous development. Moving forward, the company will enhance its research and development efforts and aim to provide high-quality medical products and services, thereby creating greater value for society